Key Drivers
- Cash Cushion
- Operating Losses
- Weak Revenue
AIAI Summary
TSHA is now a credible late-stage optionality play rather than a pure survival story, but with value still hinging almost entirely on the 6-month TSHA-102 data, FDA acceptance, and safety readout, investors should treat the recent $200M raise as runway that reduces near-term financing risk without removing dilution and binary clinical downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Operating Losses
- •Weak Revenue
TSHA has strong liquidity and ample cash, but persistent losses, negative operating cash flow, and minimal revenue make it a financially durable yet operationally weak, highly speculative stock.
Price Behavior
Key Price Behavior Insights:
- •Flat Outcome
- •Failed Rally
- •Key Support
TSHA ended last month essentially flat, with a sharp but short-lived rally from $5.46 to $6.68 that failed at $6.40-$6.70, while $5.50-$5.60 remains key support.
Sharp rise from $5.46 to $6.68, then quickly faded back to $5.95
Sentiment & News
Key News Insights:
- •Late-stage progress
- •Manufacturing readiness
- •2027 milestones
Taysha is advancing TSHA-102 toward a potential BLA by completing pivotal dosing, expanding commercial manufacturing support, and setting key 2027 regulatory and data milestones.
The update is modestly positive for the stock, as it strengthens the TSHA-102 regulatory path while keeping key efficacy and FDA feedback catalysts ahead
Similar Companies in Healthcare
Other companies in the same sector with AI ratings